Pandaomics: An AI-Driven Platform for Therapeutic Target and Biomarker Discovery

February 2024 in “ Journal of Chemical Information and Modeling ”

Petrina Kamya, Ivan V. Ozerov, Frank W. Pun, Kyle Tretina, Tatyana Fokina, Shan Chen, Vladimir Naumov, Xi Long, Sha Lin, Mikhail Korzinkin, Daniil Polykovskiy, Alex Aliper, Feng Ren, Alex Zhavoronkov

TLDR PandaOmics uses AI to find new disease treatment targets and biomarkers.

PandaOmics is a cloud-based AI platform designed for discovering therapeutic targets and biomarkers by analyzing multimodal omics and biomedical text data. It generates hypotheses for novel and repurposed targets and biomarkers, which have been validated in both in vitro and in vivo studies. As part of Insilico Medicine's Pharma.ai suite, PandaOmics works alongside Chemistry42 for creating new small molecules and inClinico for predicting clinical trial success. The platform efficiently identifies novel molecular targets and biomarkers for various diseases.

View this study on pubs.acs.org →

Pandaomics: An AI-Driven Platform for Therapeutic Target and Biomarker Discovery

Research cited in this study

research Identification of Dual-Purpose Therapeutic Targets Implicated in Aging and Glioblastoma Multiforme Using PandaOmics - An AI-Enabled Biological Target Discovery Platform

research High-Confidence Cancer Patient Stratification Through Multiomics Investigation of DNA Repair Disorders

research An Analysis of Gene Expression Data Involving Examination of Signaling Pathways Activation Reveals New Insights into the Mechanism of Action of Minoxidil Topical Foam in Men with Androgenetic Alopecia